These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37457761)

  • 21. The hidden therapist: evidence for a central role of music in psychedelic therapy.
    Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R
    Psychopharmacology (Berl); 2018 Feb; 235(2):505-519. PubMed ID: 29396616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.
    Chisamore N; Johnson D; Chen MJQ; Offman H; Chen-Li D; Kaczmarek ES; Doyle Z; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2024 Aug; 176():77-84. PubMed ID: 38850581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence.
    Koning E; Brietzke E
    Trends Psychiatry Psychother; 2024; 46():e20220597. PubMed ID: 37126863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
    Meir P; Taylor L; Soares JC; Meyer TD
    J Affect Disord; 2023 Feb; 323():748-754. PubMed ID: 36535547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
    Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D
    Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
    de la Salle S; Kettner H; Thibault Lévesque J; Garel N; Dames S; Patchett-Marble R; Rej S; Gloeckler S; Erritzoe D; Carhart-Harris R; Greenway KT
    Sci Rep; 2024 Jul; 14(1):16524. PubMed ID: 39019922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic-assisted psychotherapy: where is the psychotherapy research?
    Aday JS; Horton D; Fernandes-Osterhold G; O'Donovan A; Bradley ER; Rosen RC; Woolley JD
    Psychopharmacology (Berl); 2024 Aug; 241(8):1517-1526. PubMed ID: 38782821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
    Greenway KT; Garel N; Jerome L; Feduccia AA
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):655-670. PubMed ID: 32478631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The therapeutic potential of psilocybin: a systematic review.
    van Amsterdam J; van den Brink W
    Expert Opin Drug Saf; 2022 Jun; 21(6):833-840. PubMed ID: 35225143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethical and legal issues in psychedelic harm reduction and integration therapy.
    Pilecki B; Luoma JB; Bathje GJ; Rhea J; Narloch VF
    Harm Reduct J; 2021 Apr; 18(1):40. PubMed ID: 33827588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelic-assisted therapies: The past, and the need to move forward responsibly.
    Gardner J; Carter A; O'Brien K; Seear K
    Int J Drug Policy; 2019 Aug; 70():94-98. PubMed ID: 31136924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

  • 39. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
    Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J
    J Psychoactive Drugs; 2022; 54(4):309-318. PubMed ID: 34468293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psilocybin-assisted therapy for depression: How do we advance the field?
    Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ
    Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.